(Total Views: 383)
Posted On: 01/11/2021 3:20:45 PM
Post# of 145881
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Re: chuckles759 #72196
Chuckles,
It certainly seems that additional trials to fine tune Leronlimab use would be appropriate.
At a minimum, additional dosing and IV vs IM administration seem worthy of evaluation.
It seems that viral escape/persistence is due to wholesale immune dysfunction. As viral reproduction does not seem to be directly addressed by LL, RO would seem less critical than in HIV.
Much more to learn post CD-12
It certainly seems that additional trials to fine tune Leronlimab use would be appropriate.
At a minimum, additional dosing and IV vs IM administration seem worthy of evaluation.
It seems that viral escape/persistence is due to wholesale immune dysfunction. As viral reproduction does not seem to be directly addressed by LL, RO would seem less critical than in HIV.
Much more to learn post CD-12
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)